## COVID-19 Critical Intelligence Unit

### **Daily evidence digest**

24 September 2021

The daily evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.

# Multisystem inflammatory syndrome in adults, phase 3 trials of Spikevax and Novavax, REGEN-COV antibody combination to prevent COVID-19

#### Peer reviewed journals featured:

- · Systematic reviews on:
  - o Multisystem inflammatory syndrome in adults here
  - o Heparin-induced thrombocytopenia in COVID-19 patients here
  - o Predictors of mortality in thrombotic thrombocytopenia after adenoviral vaccination here
- A meta-analysis on the effects of different corticosteroid therapy on severe COVID-19 patients here
- Phase 3 trials of Spikevax (Moderna) <u>here</u> and Novavax vaccines <u>here</u>
- A randomised controlled trial of REGEN-COV monoclonal antibodies to prevent COVID-19 here
- Observational studies on:
  - SARS-CoV-2 screening and environmental monitoring urban public school settings here
  - o The effectiveness of mRNA vaccine among US healthcare personnel here
  - Diagnostic models for pulmonary embolism in COVID-19 patients here
  - o Interpreting cell phone mobility data during COVID-19 here
  - o Epidemiological characteristics of SARS-CoV-2 variants of concern here
- Editorials on:
  - COVID-19 vaccines for teenagers <u>here</u>
  - o Greece's use of AI to curb COVID-19 here
- Commentary on using Health Data Research UK to help tackle COVID-19 here

#### Letters and correspondence discussed:

- Monoclonal antibody treatment in high-risk Native American COVID-19 patients here
- A randomised trial of a third dose of Spikevax (Moderna) vaccine in transplant recipients here
- Fractionating COVID-19 vaccines here
- The lesson of ivermectin <u>here</u>



#### Pre-peer review articles featured:

- The removal of airborne SARS-CoV-2 and other microbial bioaerosols by air filtration here
- Viral loads and patient profiles infected with Delta, Alpha, or R.1 variants in Tokyo here
- Comparative mRNA and ChAdOx1 vaccine effectiveness including early variants of concern here
- Impact of prior SARS-CoV-2 infection on post-vaccination SARS-CoV-2 spike IgG antibodies in healthcare workers <u>here</u>
- COVID-19 acceleration and vaccine status in France here
- Real-world clinical performance of SARS-CoV-2 point-of-care diagnostic tests here
- The Delta variant had a negligible impact on COVID-19 vaccine effectiveness in the US here

#### News and blogs

- COVID-19 testing moves out of the clinic and into the home <u>here</u>
- Costs of preventable COVID-19 hospitalisations during summer in the US exceed \$5 billion here
- A machine-learning algorithm to target COVID-19 testing of travellers <u>here</u>
- Increase in myopia reported among children during COVID-19 lockdown here
- NEJM audio interview on vaccine efficacy and boosters in COVID-19 here

<u>Click here</u> to subscribe to the daily evidence digest.

#### **Living Evidence Tables**

Living Evidence tables are up-to-date summaries of emerging evidence. Tables are available on <u>COVID-19 transmission</u>, SARS-CoV-2 <u>vaccines</u>, and <u>variants</u> of concern, <u>post-acute sequelae of COVID-19</u> (PASC), surgery and COVID-19, and rapid testing.



The daily evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.